These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38147492)

  • 1. Disease latency and new-user versus prevalent-user cohort designs: Implications for pharmacoepidemiology in dementia.
    Wu CY; Swardfager W
    J Am Geriatr Soc; 2024 Mar; 72(3):953-955. PubMed ID: 38147492
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: Disease latency and new-user versus prevalent-user cohort designs: Implications for pharmacoepidemiology in dementia.
    Lee AK; Lee SJ; Dublin S
    J Am Geriatr Soc; 2024 Mar; 72(3):956-957. PubMed ID: 38147504
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores.
    Suissa S; Moodie EE; Dell'Aniello S
    Pharmacoepidemiol Drug Saf; 2017 Apr; 26(4):459-468. PubMed ID: 27610604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-user and prevalent-user designs and the definition of study time origin in pharmacoepidemiology: A review of reporting practices.
    Luijken K; Spekreijse JJ; van Smeden M; Gardarsdottir H; Groenwold RHH
    Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):960-974. PubMed ID: 33899305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invited Commentary: The Prevalent New-User Design in Pharmacoepidemiology-Challenges and Opportunities.
    Filion KB; Yu YH
    Am J Epidemiol; 2021 Jul; 190(7):1349-1352. PubMed ID: 33350439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods in pharmacoepidemiology.
    Sommet A; Pariente A
    Therapie; 2019 Apr; 74(2):187-197. PubMed ID: 30819408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review.
    Gault N; Castañeda-Sanabria J; De Rycke Y; Guillo S; Foulon S; Tubach F
    BMC Med Res Methodol; 2017 Feb; 17(1):25. PubMed ID: 28178924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.
    Roberts AW; Dusetzina SB; Farley JF
    J Comp Eff Res; 2015 Jan; 4(1):27-35. PubMed ID: 25565067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underuse of self-controlled designs in pharmacoepidemiology in electronic healthcare databases: a systematic review.
    Gault N; Castañeda-Sanabria J; Guillo S; Foulon S; Tubach F
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):372-7. PubMed ID: 26781227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Core concepts in pharmacoepidemiology: Fundamentals of the cohort and case-control study designs.
    Pottegård A
    Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):817-826. PubMed ID: 35621007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. User-only design to assess drug effectiveness in clinical practice: application to bisphosphonates and secondary prevention of fractures.
    Corrao G; Ghirardi A; Segafredo G; Zambon A; Della Vedova G; Lapi F; Cipriani F; Caputi A; Vaccheri A; Gregori D; Gesuita R; Vestri A; Staniscia T; Mazzaglia G; Di Bari M;
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):859-67. PubMed ID: 24911392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies addressing inadequate information on health factors in pharmacoepidemiology studies relying on healthcare databases: commentary from a public workshop.
    Eworuke E; Shaya F; Graham DJ; Major J; Levenson M; Chen CY; Leishear K; Pinheiro S
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):998-1001. PubMed ID: 27385063
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacoepidemiology.
    Evans SJ
    Br J Clin Pharmacol; 2012 Jun; 73(6):973-8. PubMed ID: 22360737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies.
    Acton EK; Willis AW; Hennessy S
    Pharmacoepidemiol Drug Saf; 2023 Jan; 32(1):9-18. PubMed ID: 36216785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study designs in paediatric pharmacoepidemiology.
    Verhamme K; Sturkenboom M
    Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():67-74. PubMed ID: 21107830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research on drug safety and effectiveness using pharmacoepidemiological databases.
    Andersen M
    J Intern Med; 2014 Jun; 275(6):548-50. PubMed ID: 24635741
    [No Abstract]   [Full Text] [Related]  

  • 17. Utilization of health care databases for pharmacoepidemiology.
    Takahashi Y; Nishida Y; Asai S
    Eur J Clin Pharmacol; 2012 Feb; 68(2):123-9. PubMed ID: 21808989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inventory of real-world data sources in Japan: Annual survey conducted by the Japanese Society for Pharmacoepidemiology Task Force.
    Kumamaru H; Togo K; Kimura T; Koide D; Iihara N; Tokumasu H; Imai S
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5680. PubMed ID: 37650434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-related biases in pharmacoepidemiology.
    Suissa S; Dell'Aniello S
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1101-1110. PubMed ID: 32783283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating medication effects outside of clinical trials: new-user designs.
    Ray WA
    Am J Epidemiol; 2003 Nov; 158(9):915-20. PubMed ID: 14585769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.